During the past decade, University General Hospital Attikon conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 15 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 11 clinical trials were completed. i.e. 44% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University General Hospital Attikon" #1 sponsor was "Boehringer Ingelheim" with 7 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Pfizer" with 5 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Incyte Corporation" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University General Hospital Attikon" #1 collaborator was "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Chugai" with 1 trials as a collaborator, "Da Volterra" with 1 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "University General Hospital Attikon" are "Multiple Myeloma" (4 trials), "Pulmonary Arterial Hypertension" (4 trials), "Idiopathic Pulmonary Fibrosis" (3 trials), "Lupus Nephritis" (2 trials) and "Urinary Bladder Neoplasms" (2 trials). Many other conditions were trialed in "University General Hospital Attikon" in a lesser frequency.

Most popular intervention types in "University General Hospital Attikon" are "Drug" (31 trials), "Biological" (5 trials), "Other" (4 trials), "Device" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Bortezomib" (4 trials), "Carboplatin" (3 trials), "Cisplatin" (3 trials) and "Dexamethasone" (3 trials). Other intervention names were less common.

The vast majority of trials in "University General Hospital Attikon" are 41 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University General Hospital Attikon". 1 are not yet recruiting, 13 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in University General Hospital Attikon, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University General Hospital Attikon, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".